Pseudomyxoma Peritonei Clinical Trial
Official title:
Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy
Verified date | March 2023 |
Source | Mercy Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the impact of antibiotic therapy on the disease progression and overall survival of patients with Pseudomyxoma Peritonei (PMP).
Status | Active, not recruiting |
Enrollment | 80 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - Patients must have measurable pseudomyxoma peritonei from appendiceal origin, confirmed by histology, cytology, or radiographical evidence - - Age = 21 years - Eastern Cooperative Oncology Group (ECOG) performance status score=2/Karnofsky performance status of (KPS) = 70% (see Appendix B) - Patients must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) =1,000/mm3 Platelets =100,000/mm3 Hemoglobin = 8.5 g/dL Renal function: Creatinine =1.5 times the upper limit of normal (ULN) or calculated creatinine clearance =60ml/min Hepatic function: Bilirubin =1.5 times ULN Alanine aminotransferase (ALT) =3 times ULN Aspartate aminotransferase (AST) =3 times ULN - Ability of subject or Legally Authorized Representative (LAR) to understand and willingness to sign a written informed consent, approved by Mercy Medical Center Institutional Review Board (IRB) - A negative pregnancy test for women of childbearing age with all reproductive organs intact Exclusion Criteria: - Patients receiving any other investigational agents - Presence of other invasive malignancies or evidence of another cancer present within the last 3 years, excluding skin cancer - history of, or known allergic reaction/hypersensitivity to PREVPAC or any component of similar chemical or biologic composition to PREVPAC - Patients < 21 of age - Pregnancy or lactation at the time of proposed assignment. Pregnant women are excluded from this study because PREVPAC is based on the pregnancy category for clarithromycin which is Category C agent with the potential for teratogenic or abortifacient effects. These potential risks may also apply to CRS/HIPEC. - Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol (e.g., unable to swallow pills) - Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or giving informed consent - Known active acute hepatitis and confirmed diagnosis of Human Immunodeficiency Virus (HIV) infection. HIV-positive patients on combination antiretroviral therapy are ineligible. These patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. - Active systemic infection that requires use of parenteral antibiotics - Renal insufficiency with serum creatinine level =1.5 times the upper limit of normal or calculated - - Patients with concurrent severe medical problems unrelated to malignancy that will preclude compliance with the study or places at an unacceptable risk for participation in the study determinate by study investigators - Patients to be maintained on any medication having severe interactions with PREVPAC |
Country | Name | City | State |
---|---|---|---|
United States | Mercy Medical Center | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Mercy Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Tolerance and safety of PrevPac administration | Rate of morbidity and mortality | Through 14 day treatment therapy | |
Other | Analyze number of live bacteria in PMP tumor and mucin | In situ hybridization [ISH], either bright light or fluorescence in situ hybridization [FISH] | through study completion, an average of 5 years | |
Primary | Overall survival | Kaplan-Meier survival estimates | 5 year | |
Secondary | Progression-free survival measured by no evidence of disease progression, i.e. tumor markers within normal limits, no radiographical evidence of disease | Kaplan-Meier survival estimates | 5 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04024917 -
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
|
N/A | |
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Active, not recruiting |
NCT01427101 -
Results of CRS and Debulking in PMP Patients
|
N/A | |
Active, not recruiting |
NCT04982146 -
Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei
|
Phase 1 | |
Completed |
NCT04088786 -
Phase I Trial HIPEC With Nal-irinotecan
|
Phase 1 | |
Not yet recruiting |
NCT06084780 -
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
|
Phase 2 | |
Active, not recruiting |
NCT02834169 -
French National Registry of Rare Peritoneal Surface Malignancies
|
N/A | |
Completed |
NCT01764789 -
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
|
N/A | |
Completed |
NCT02040142 -
Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C
|
Phase 2 | |
Withdrawn |
NCT04125225 -
What Are the Experiences of Patients With Pseudomyxoma Peritonei?
|
||
Not yet recruiting |
NCT03976973 -
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
|
Phase 2 | |
Recruiting |
NCT01617382 -
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
|
||
Completed |
NCT01652794 -
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
|
Phase 1 | |
Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
Completed |
NCT05513183 -
Severe Neutropenia After HIPEC Using Mitomycin-C
|
||
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Recruiting |
NCT03210298 -
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
|
||
Terminated |
NCT04665921 -
A Study of SGN-STNV in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05321329 -
Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients
|
Phase 2 |